Abstract
Preeclampsia is a serious condition that affects about five percent of pregnant women. The disorder itself or related complications are responsible for a significant percentage of maternal and fetal morbidity, even in developed countries.
Although our understanding of etiology is still limited, the possibility of detecting and evaluating certain angiogenic factors by the end of the first trimester gives food for thought about prospects for preeclampsia prevention. Secondary prevention is currently based mostly on the effort to pharmacologically affect the spiral artery transformation and development of the abnormal placental microcirculation which lead to clinical symptoms of preeclampsia.
The preventive treatment options are narrow. Greatest effect was noted with acetylsalicylic acid medication in the at-risk population.
The dose of 75-150 mg per day is considered optimal. The treatment should start before the 16th gestational week; later initiation of therapy is associated with considerably smaller effect.
The incidence of the early-onset preeclampsia (<34th gestational week) can be reduced up to 50% while preventive treatment affects the late-onset preeclampsia only minimally. Calcium supplementation is effective only in women with low calcium intake.
Question for the future as well as subject of several studies is a clinical significance of low molecular weight heparin and sildenafil.